Tag Archives: GSK

UK Pharma/Bio Responds to 'Predictable' Budget

UK pharma and biopharma was quick to respond positively to the Chancellor of the Exchequer’s annual Budget speech last week, despite some industry disappointment at a fiscal program widely derided as safe, neutral, and, in Andrew Goodwin of Ernst & Young’s words, “one of the most predictable” of recent times. 
Posted in Global | Also tagged , , , , | Leave a comment

GlaxoSmithKline Recalls Antihypertensive Drug Made at Novartis Facility

By Patricia Van Arnum. GlaxoSmithKline is recalling 394,230 bottles containing its antihypertensive drug DynaCirc CR (isradipine) controlled-release tablets, according to a Feb. 22, 2012, FDA enforcement report. The lots are being recalled due to concerns regarding the level of cGMP compliance and procedural controls related to line clearance during the packing process at the Lincoln, […]
Posted in Regulatory, Safety | Also tagged , , | 1 Comment

Witty Touts GSK Pipeline in 4th Quarter Review

Posted in Emerging Markets, Europe, Global, News, R&D, Strategy | Also tagged , , , , , | Leave a comment

Arise Sir Andrew (Witty)

Big Pharma received a nod in the UK’s New Year’s Honours List this week when a knighthood was duly bestowed upon GSK’s Andrew Witty — making him ‘Sir Andrew’ to you and me. For once, though, receiving such an honor did not exactly place him in totally exalted company.
Posted in Global, leadership, Op-Ed | Also tagged , , | Leave a comment

It's Industry's Problem: A Fresh Take on R&D Costs

High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what […]
Posted in Global, IP, leadership, R&D | Also tagged , , , | 2 Comments
  • Categories

  • Meta